Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy PDS Biotechnology Corporation stock

Own PDS Biotechnology Corporation stock in just a few minutes.

PDS Biotechnology Corporation is a biotechnology business based in the US. PDS Biotechnology Corporation shares (PDSB) are listed on the NASDAQ and all prices are listed in US Dollars. PDS Biotechnology Corporation employs 15 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in PDS Biotechnology Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PDSB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

PDS Biotechnology Corporation share price

Use our graph to track the performance of PDSB stocks over time.

PDS Biotechnology Corporation shares at a glance

Information last updated 2021-04-21.
52-week range$0.81 - $6.35
50-day moving average $4.77
200-day moving average $3.30
Wall St. target price$8.35
PE ratio 24.9573
Dividend yield N/A (0%)
Earnings per share (TTM) $0.12

Buy PDS Biotechnology Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PDS Biotechnology Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is PDS Biotechnology Corporation under- or over-valued?

Valuing PDS Biotechnology Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PDS Biotechnology Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

PDS Biotechnology Corporation's P/E ratio

PDS Biotechnology Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, PDS Biotechnology Corporation shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

PDS Biotechnology Corporation financials

Gross profit TTM $0
Return on assets TTM -41.05%
Return on equity TTM -76.48%
Profit margin 0%
Book value $1.22
Market capitalisation $114.9 million

TTM: trailing 12 months

Shorting PDS Biotechnology Corporation shares

There are currently 304,956 PDS Biotechnology Corporation shares held short by investors – that's known as PDS Biotechnology Corporation's "short interest". This figure is 62.6% down from 816,297 last month.

There are a few different ways that this level of interest in shorting PDS Biotechnology Corporation shares can be evaluated.

PDS Biotechnology Corporation's "short interest ratio" (SIR)

PDS Biotechnology Corporation's "short interest ratio" (SIR) is the quantity of PDS Biotechnology Corporation shares currently shorted divided by the average quantity of PDS Biotechnology Corporation shares traded daily (recently around 2.5 million). PDS Biotechnology Corporation's SIR currently stands at 0.12. In other words for every 100,000 PDS Biotechnology Corporation shares traded daily on the market, roughly 120 shares are currently held short.

However PDS Biotechnology Corporation's short interest can also be evaluated against the total number of PDS Biotechnology Corporation shares, or, against the total number of tradable PDS Biotechnology Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PDS Biotechnology Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 PDS Biotechnology Corporation shares in existence, roughly 10 shares are currently held short) or 0.016% of the tradable shares (for every 100,000 tradable PDS Biotechnology Corporation shares, roughly 16 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PDS Biotechnology Corporation.

Find out more about how you can short PDS Biotechnology Corporation stock.

PDS Biotechnology Corporation share dividends

We're not expecting PDS Biotechnology Corporation to pay a dividend over the next 12 months.

Have PDS Biotechnology Corporation's shares ever split?

PDS Biotechnology Corporation's shares were split on a 1:20 basis on 17 March 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PDS Biotechnology Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for PDS Biotechnology Corporation shares which in turn could have impacted PDS Biotechnology Corporation's share price.

PDS Biotechnology Corporation share price volatility

Over the last 12 months, PDS Biotechnology Corporation's shares have ranged in value from as little as $0.81 up to $6.35. A popular way to gauge a stock's volatility is its "beta".

PDSB.US volatility(beta: 2.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PDS Biotechnology Corporation's is 2.0721. This would suggest that PDS Biotechnology Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

PDS Biotechnology Corporation overview

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U. S. Department of Health and Human Services, and MSD International GmbH.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site